We are seeking an experienced and motivated structural biologist to join the Protein Sciences and Lead Discovery team at Kymera Therapeutics. As part of a dynamic team, the successful candidate will provide critical structural support (both x-ray crystallography and cryo-electron microscopy) for the identification and optimization of ligands to novel and proprietary E3 ligases as well as “undruggable” proteins of interest and will both conduct internal and drive external experiments to advance projects toward their goals. Kymera is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. This position will also play an important role in the progression of these binders to degraders. The successful candidate will work in a fast-paced and highly matrixed discovery environment requiring scientific rigor, organized and independently driven work, and exceptional attention to detail.
Kymera Therapeutics is a clinical stage biotechnology company focused on advancing the field of targeted protein degradation (TPD), a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ TPD platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Our mission is to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation. Kymera’s goal is to become a fully integrated biopharmaceutical company with a pipeline of novel medicines, with an initial focus on immune-inflammatory diseases and oncology.
In 2021, we plan to continue to grow and strengthen our organizational capabilities to deliver on the potential of inventing a new class of protein degrader medicines for patients. Kymera is rapidly advancing three programs in clinical studies this year. We are also actively advancing a broad pipeline of preclinical programs across a wide variety of diseases, both internally and in collaboration with our partners Sanofi and Vertex Pharmaceuticals.
Responsibilities:
Qualifications: